| Literature DB >> 31824192 |
Ci-Qiu Yang1, Fei Ji1, Hong-Fei Gao1, Liu-Lu Zhang1, Mei Yang1, Teng Zhu1, Min-Yi Chen1, Jie-Qing Li1, Kun Wang1.
Abstract
BACKGROUND: Nipple-sparing mastectomy (NSM) is becoming increasingly accepted as a treatment for breast disease; however, nipple-areolar complex (NAC) necrosis, a frequent severe postoperative complication, inhibits the popularity of this procedure. This study reports the technical aspects and short-term postoperative outcomes of NSM.Entities:
Keywords: breast cancer; nipple-areolar complex; nipple-sparing mastectomy; sharp dissection
Year: 2019 PMID: 31824192 PMCID: PMC6900313 DOI: 10.2147/CMAR.S230787
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Figure 1Tissue underneath the nipple-areolar complex (NAC).
Patients' Characteristics
| Characteristic | n/N | % |
|---|---|---|
| Median age at surgery: Years (Range) | 42(24–70) | |
| Disease | ||
| Breast cancer | 83/110 | 75.45% |
| Flat epithelial atypia | 2/110 | 1.82% |
| Papilloma | 4/110 | 3.64% |
| Hyperplastic pain | 7/110 | 6.36% |
| Repeated multiple fibroma | 1/110 | 0.91% |
| Serous mastitis | 1/110 | 0.91% |
| Side effect after injecting Amazingel | 3/110 | 2.73% |
| Gynecomastia | 9/110 | 8.18% |
| Histologic tumor type | ||
| Invasive | 61/83 | 73.49% |
| DCIS | 22/83 | 26.51% |
| Tumor size | ||
| ≤2 cm | 50/83 | 60.24% |
| ≤5 cm and >2 cm | 31/83 | 37.35% |
| >5 cm | 2/83 | 2.41% |
| Immunohistochemistry | ||
| ER/PR positive | 46/61 | 75.41% |
| Her-2 positive | 16/61 | 26.23% |
| Triple negative | 4/61 | 6.56% |
| Therapy before operation | ||
| Neoadjuvant chemotherapy | 18/61 | 29.51% |
| Neoadjuvant endocrine therapy | 5/61 | 8.20% |
| Lymph node | ||
| Positive | 16/61 | 26.23% |
| Negative | 45/61 | 73.77% |
Figure 2Right breast cancer with nipple-sparing mastectomy and direct implant reconstruction: postoperative view at 3 months.
Figure 3Right breast cancer with nipple-sparing mastectomy and tissue expander reconstruction.